健康系统人群中COL4A5变异的基因型优先分析与表型严重程度
基于Geisinger MyCode DiscovEHR队列的基因型优先分析显示,X连锁Alport综合征表型谱比既往已知更广;p.Gly624Asp变异者肾脏风险较低;许多患者未被诊断,未接受规范检测和治疗。
要点
- p.Gly624Asp变异者肾脏风险低于非p.Gly624Asp变异者。
- 仅47%的COL4A5变异者完成白蛋白尿筛查,少数使用RAAS抑制剂。
- 仅38%男性和16%女性有Alport综合征或薄基底膜病诊断。
核心结论
- 基因型优先分析显示X连锁Alport综合征在男女中表型谱更广、严重程度差异更大,且与基因型相关。
研究设计与样本
- 基于Geisinger MyCode DiscovEHR未选择健康系统队列,含外显子测序和电子健康记录,采用基因型优先方法。
- COL4A5致病/可能致病变异或蛋白截断变异者按社会人口学、糖尿病诊断和首次门诊年份与最多5名无COL4A3/4/5变异对照匹配。
主要发现
- 170856例中,29例半合子男性(平均52岁,SD20)和55例杂合子女性(平均59岁,SD19)携带COL4A5致病/可能致病变异,其中48例为p.Gly624Asp。
- 总体外显率(任一Alport综合征表型特征):非p.Gly624Asp变异男性94%、女性85%;p.Gly624Asp男性77%、女性69%;对照男性32%、女性50%。
- 肾衰竭比例:非p.Gly624Asp男性44%;p.Gly624Asp男性15%;非p.Gly624Asp女性10%;对照男性3%、女性2%。
- 仅47%的COL4A5患者完成白蛋白尿筛查,少数使用肾素-血管紧张素-醛固酮系统抑制剂。
- 仅38%男性和16%女性有已知Alport综合征或薄基底膜病诊断。
临床怎么用
- 对COL4A5变异者应提高Alport综合征诊断意识,并加强白蛋白尿筛查和RAAS抑制剂使用。
- p.Gly624Asp变异者肾脏风险相对较低,但仍有表型外显,需个体化监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In an unselected health system–based research study, we show that the phenotypic spectrum of X-linked Alport syndrome is wider than previously known. Kidney risks were lower for patients with p.Gly624Asp, a hypomorphic variant that is thought to have originated in Central and Eastern Europe. Many patients in this study had not been diagnosed with Alport syndrome, and consequently, many had not received appropriate testing and treatment. BACKGROUND: Our knowledge of X-linked Alport syndrome comes mostly from selected cohorts with more severe disease. METHODS: We examined the phenotypic spectrum of X-linked Alport syndrome in men and women with a genotype-based approach using data from the Geisinger MyCode DiscovEHR study, an unselected health system–based cohort with exome sequencing and electronic health records. Patients with COL4A5 variants reported as pathogenic or likely pathogenic in ClinVar, or protein-truncating variants, were each matched with up to five controls without COL4A3/4/5 variants by sociodemographics, diabetes diagnosis, and year of first outpatient encounter. Phenotypes examined included dipstick hematuria, bilateral sensorineural hearing loss, proteinuria, lower eGFR, and kidney failure. RESULTS: Of 170,856 patients, there were 29 hemizygous men (mean age 52 years [SD 20]) and 55 heterozygous women (mean age 59 years [SD 19]) with a pathogenic/likely pathogenic COL4A5 variant, including 48 with the hypomorphic variant p.Gly624Asp. Overall, penetrance (having any Alport syndrome phenotypic feature) was the highest for non-p.Gly624Asp variants (men: 94%, women: 85%) and intermediate for p.Gly624Asp (men: 77%, women: 69%) compared with controls (men: 32%, women: 50%). The proportion with kidney failure was the highest for men with non-p.Gly624Asp variants (44%) and intermediate for men with p.Gly624Asp (15%) and women with non-p.Gly624Asp variants (10%) compared with controls (men: 3%, women: 2%). Only 47% of patients with COL4A5 had completed albuminuria screening, and a minority were taking renin-angiotensin-aldosterone system inhibitors. Only 38% of men and 16% of women had a known diagnosis of Alport syndrome or thin basement membrane disease. CONCLUSIONS: Using a genotype-first approach, we show that men and women with X-linked Alport syndrome are at higher risk of related phenotypic features with a wider spectrum of severity than has been described previously and variability by genotype.
引用
- Zellers M, Solanki K, Kelly MA, et al. Genotype-First Analysis in an Unselected Health System-Based Population and Phenotypic Severity of COL4A5 Variants. J Am Soc Nephrol. 2024. PMID: 39625784. doi:10.1681/ASN.0000000580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。